European Commission Approves J&J’s Subcutaneous DARZALEX®-Based Four-Drug Regimen for Newly Diagnosed Multiple Myeloma, With or Without Transplant (https://www.myeloma.org/news-events/multiple-myeloma-news/european-commission-approves-subcutaneous-darzalex-for-ndmm)